Targeting K-Ras(G12C) mutations in cancer with a new treatment approach
Proximity-triggered, mutant-specific modification of K-Ras(G12C) with local polypharmaceutical release
This study is testing a new treatment for certain types of cancer, like non-small cell lung and colorectal cancers, that have a specific mutation called K-Ras(G12C), and it aims to make the treatment work better while being gentler on the body.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cold Spring Harbor Laboratory NIH-funded |
| Lab location | 1 site (Cold Spring Harbor, United States) |
| Project ID | NIH-11034459 on NIH RePORTER |
What this research studies
This research focuses on developing a novel treatment for cancers driven by the K-Ras(G12C) mutation, which is common in non-small cell lung and colorectal cancers. The approach involves creating a multi-functional prodrug that can target multiple pathways simultaneously, potentially improving treatment efficacy while reducing toxicity. By using a unique method called group transfer, the treatment aims to covalently modify the K-Ras(G12C) protein, leading to its degradation and enhancing the release of cytotoxic agents. This innovative strategy seeks to overcome the limitations of current therapies and provide a more effective cancer treatment option.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with non-small cell lung cancer or colorectal cancer that harbor the K-Ras(G12C) mutation.
Not a fit: Patients without the K-Ras(G12C) mutation or those with other types of cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a more effective treatment for patients with K-Ras(G12C) mutation-driven cancers, potentially improving survival rates and reducing side effects.
How similar studies have performed: While the approach of using targeted prodrugs is innovative, similar strategies targeting oncogenic mutations have shown promise in other studies, indicating potential for success.
Where this research is happening
Cold Spring Harbor, United States
- Cold Spring Harbor Laboratory — Cold Spring Harbor, United States (Active)
Researchers
- Principal investigator: Moses, John Edward — Cold Spring Harbor Laboratory
- Study coordinator: Moses, John Edward
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.